Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO

Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO

(RTTNews) – The biotech industry witnessed several key events this week, including major FDA approvals, acquisitions, pivotal clinical trial results and setbacks. • A series of FDA approvals were announced during the week, with GSK, Halozyme Therapeutics, Femasys, Johnson & Johnson, Amphastar Pharma, and Fortress Biotech getting the go-ahead to market their respective therapeutic candidates. … Read more

Client Challenge

Client Challenge

Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser. #Client #Challenge

Cantor Keeps Overweight on AMD Despite Target Cut, Citing Strong AI Tailwinds

Cantor Keeps Overweight on AMD Despite Target Cut, Citing Strong AI Tailwinds

Advanced Micro Devices, Inc. (NASDAQ:AMD) is included among the 12 Best Long Term US Stocks to Buy Now. Cantor Keeps Overweight on AMD Despite Target Cut, Citing Strong AI Tailwinds On December 16, Cantor Fitzgerald cut its price target on Advanced Micro Devices, Inc. (NASDAQ:AMD) to $300 from $350 while keeping an Overweight rating on … Read more

Client Challenge

Client Challenge

Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser. #Client #Challenge

×